Helicobacter Pylori, Atrophic Gastritis and Intestinal Metaplasia Registry and Prospective Study

Launched by CHINESE UNIVERSITY OF HONG KONG · Sep 13, 2021

Keywords

ClinConnect Summary

This clinical trial is focused on understanding the relationship between Helicobacter pylori (a type of bacteria that can cause stomach issues), atrophic gastritis (a condition where the stomach lining becomes thin), and intestinal metaplasia (a change in the stomach lining that may lead to cancer). Researchers want to learn more about what factors might cause these conditions to progress and how often patients should be monitored for potential health problems. To do this, they are creating a registry to follow patients over time.

To participate in this study, you need to be at least 18 years old and have a current or past infection with Helicobacter pylori, as well as a diagnosis of atrophic gastritis, intestinal metaplasia, or gastric cancer (after treatment). Participants will be asked to provide consent, complete questionnaires, and share some medical samples for research. The study is currently recruiting individuals of all genders, and it aims to gather important information that could improve care for patients with these conditions in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adults \>= 18 years of age
• • Written informed consent obtained
• • Diagnosed with current or past H. pylori infection,
• • Histologically proven atrophic gastritis (body and/or antrum of stomach), intestinal metaplasia (complete and incomplete), dysplasia (any grade) and/or gastric cancer (post- treatment)
• Exclusion Criteria:
• • Co-morbid illness that prohibit endoscopic surveillance
• • Declines for study questionnaire, biobanking of specimens and/or regular review per study protocol